pharminent

• Other

ASCO26: Symptom-tracking app helps advanced cancer patients

pharminent June 2, 2026

• M&A / Deals

Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn

pharminent June 2, 2026

• Clinical Data

ASCO26: AZ triplet makes waves in frontline liver cancer

pharminent June 2, 2026

• News

pharminent June 2, 2026

• M&A / Deals

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

pharminent June 1, 2026

• M&A / Deals

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

pharminent June 1, 2026

• Clinical Data

ASCO: Summit reached with China lung data but new climb begins to prove global benefit

pharminent June 1, 2026

• M&A / Deals

Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide

pharminent June 1, 2026

• Regulatory

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

pharminent June 1, 2026

• News

pharminent June 1, 2026

• Clinical Data

pharminent May 31, 2026

• Clinical Data

ASCO: BMS hails “compelling” phase 3 celmod readout

pharminent May 29, 2026

• Clinical Data

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

pharminent May 29, 2026

• Regulatory

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

pharminent May 29, 2026

• Regulatory

FDA delays verdict on Beren’s rare disease drug by three months

pharminent May 29, 2026

• M&A / Deals

Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent

pharminent May 29, 2026

• Market Access

GSK’s Nucala secures NICE COPD endorsement

pharminent May 29, 2026

• Regulatory

Ahead of ASCO data drop, AZ gets key Imfinzi approval

pharminent May 29, 2026

• Market Access

Medicare Advantage Out-of-Pocket Limits: Variation and Trends

pharminent May 28, 2026

• Clinical Data

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

pharminent May 28, 2026

• Commercial

CVS obesity drug deal puts Lilly on equal footing with Novo

pharminent May 28, 2026

• Market Access

France ‘first EU country to cover obesity drugs’

pharminent May 28, 2026

• Clinical Data

GSK hails ‘unprecedented’ cure rates with hep B drug

pharminent May 28, 2026

• Regulatory

AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

pharminent May 28, 2026

• Regulatory

November date set for FDA decision on Sanofi’s Gaucher drug

pharminent May 28, 2026

• News

pharminent May 27, 2026

• Clinical Data

Kailera’s three-pronged obesity shot shows promise in early trial

pharminent May 27, 2026

• M&A / Deals

Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss

pharminent May 27, 2026

• Commercial

Kardigan targets IPO to support cardiology pipeline progression

pharminent May 27, 2026

• Regulatory

FDA delays verdict on AZ breast cancer drug

pharminent May 27, 2026

• Clinical Data

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

pharminent May 26, 2026

• M&A / Deals

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

pharminent May 26, 2026

• Clinical Data

Arthrosi drug trial in gout delivers for new owner Sobi

pharminent May 26, 2026

• Clinical Data

Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study

pharminent May 26, 2026

• Regulatory

Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC

pharminent May 26, 2026

• Other

All eyes on Revolution, bispecific antibodies and more at ASCO26

pharminent May 26, 2026

• News

pharminent May 26, 2026

• Clinical Data

Parkinson’s drug from Biogen, Denali comes up short

pharminent May 22, 2026

• Clinical Data

Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival

pharminent May 22, 2026

• M&A / Deals

Gilead inks $140M API supply deal, tightening ties to Korean manufacturer

pharminent May 22, 2026